Optimal hematocrit in an artificial microvascular network

Transfusion

Volumn 57, Issue 9, 2017, Pages 2257-2266

  Piety, Nathaniel Z ^a   Reinhart, Walter H ^b   Stutz, Julianne ^a   Shevkoplyas, Sergey S ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ARTIFICIAL MICROVASCULAR NETWORK; BLOOD AUTOTRANSFUSION; BLOOD VISCOSITY; CONTROLLED STUDY; ERYTHROCYTE; HEMATOCRIT; HUMAN; IN VITRO STUDY; LEUKOCYTE; MICROFLUIDICS; MICROVASCULATURE; NORMAL HUMAN; OXYGEN TRANSPORT; PERFUSION PRESSURE; SHEAR RATE; TISSUE OXYGENATION; ANEMIA; BIOLOGICAL MODEL; BLOOD; BLOOD PRESSURE; METABOLISM; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PHYSIOLOGY;

OXYGEN;

ANEMIA; BLOOD PRESSURE; BLOOD VISCOSITY; HEMATOCRIT; HUMANS; MICROVESSELS; MODELS, CARDIOVASCULAR; OXYGEN; OXYGEN CONSUMPTION;

EID: 85021821687     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14213     Document Type: Article

References (62)

1. Crowell JW, Smith EE. Determinant of the optimal hematocrit. J Appl Physiol 1967;22:501-4.
2. Stark H, Schuster S. Comparison of various approaches to calculating the optimal hematocrit in vertebrates. J Appl Physiol (1985) 2012;113:355-67.
3. Reinhart WH. The optimum hematocrit. Clin Hemorheol Microcirc 2016;64:575-85.
4. Van Tiel E, Peeters PHM, Smit HA, et al. Quitting smoking may restore hematological characteristics within five years. Ann Epidemiol 2002;12:378-88.
5. Jelkmann W, Lundby C. Blood doping and its detection. Blood 2011;118:2395-404.
6. Annaheim S, Jacob M, Krafft A, et al. RhEPO improves time to exhaustion by non-hematopoietic factors in humans. Eur J Appl Physiol 2016;116:623-33.
7. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90.
8. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
9. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-42.
10. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32.
11. Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010;153:23-33.
12. Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013;368:1210-9.
13. Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: a clinical practice guideline from the AABB*. Ann Intern Med 2012;157:49-58.
14. Lacroix J, Tucci M, Du Pont-Thibodeau G. Red blood cell transfusion decision making in critically ill children. Curr Opin Pediatr 2015;27:286-91.
15. Pirofsky B. The determination of blood viscosity in man by a method based on Poiseuille's law. J Clin Invest 1953;32:292-8.
16. Stone HO, Thompson HK Jr, Schmidt-Nielsen K. Influence of erythrocytes on blood viscosity. Am J Physiol 1968;214:913-8.
17. Stadler AA, Zilow EP, Linderkamp O. Blood viscosity and optimal hematocrit in narrow tubes. Biorheology 1990;27:779-88.
18. Linderkamp O, Stadler AA, Zilow EP. Blood viscosity and optimal hematocrit in preterm and full-term neonates in 50- to 500-micrometer tubes. Pediatr Res 1992;32:97-102.
19. McKay CB, Meiselman HJ. Osmolality- and hematocrit-mediated flow behavior of RBC suspensions in 33 micrometer ID tubes. Biorheology 1989;26:863-74.
20. Bogar L, Juricskay I, Kesmarky G, et al. Erythrocyte transport efficacy of human blood: a rheological point of view. Eur J Clin Invest 2005;35:687-90.
21. Withers PC, Hillman SS, Hedrick MS, et al. Optimal hematocrit theory during activity in the bullfrog (Rana catesbeiana). Comp Biochem Physiol A Comp Physiol 1991;99(1-2):55-60.
22. Kiel JW, Shepherd AP. Optimal hematocrit for canine gastric oxygenation. Am J Physiol 1989;256:H472-7.
23. Pries AR, Secomb TW, Gaehtgens P, et al. Blood flow in microvascular networks. Experiments and simulation. Circ Res 1990;67:826-34.
24. Kiani MF, Pries AR, Hsu LL, et al. Fluctuations in microvascular blood flow parameters caused by hemodynamic mechanisms. Am J Physiol 1994;266:H1822-8.
25. Forouzan O, Yang X, Sosa JM, et al. Spontaneous oscillations of capillary blood flow in artificial microvascular networks. Microvasc Res 2012;84:123-32.
26. Pries AR, Secomb TW. Rheology of the microcirculation. Clin Hemorheol Microcirc 2003;29:143-8.
27. Pries AR, Kuebler WM. Normal endothelium. Handb Exp Pharmacol 2006;176(pt 1):1-40.
28. Shevkoplyas SS, Gifford SC, Yoshida T, et al. Prototype of an in vitro model of the microcirculation. Microvasc Res 2003;65:132-6.
29. Shevkoplyas SS, Yoshida T, Gifford SC, et al. Direct measurement of the impact of impaired erythrocyte deformability on microvascular network perfusion in a microfluidic device. Lab Chip 2006;6:914-20.
30. Burns JM, Yang X, Forouzan O, et al. Artificial microvascular network: a new tool for measuring rheologic properties of stored red blood cells. Transfusion 2012;52:1010-23.
31. Sosa JM, Nielsen ND, Vignes SM, et al. The relationship between red blood cell deformability metrics and perfusion of an artificial microvascular network. Clin Hemorheol Microcirc 2014;57:275-89.
32. Piety NZ, Reinhart WH, Pourreau PH, et al. Shape matters: the effect of red blood cell shape on perfusion of an artificial microvascular network. Transfusion 2016;56:844-51.
33. Reinhart WH, Piety NZ, Shevkoplyas SS. Influence of red blood cell aggregation on perfusion of an artificial microvascular network. Microcirculation 2017;24:e12317.
34. Reinhart WH, Piety NZ, Goede JS, et al. Effect of osmolality on erythrocyte rheology and perfusion of an artificial microvascular network. Microvasc Res 2015;98:102-7.
35. Burns JM, Yoshida T, Dumont LJ, et al. Deterioration of red blood cell mechanical properties is reduced in anaerobic storage. Blood Transfus 2016;14:80-8.
36. Reinhart WH, Piety NZ, Deuel JW, et al. Washing stored red blood cells in an albumin solution improves their morphologic and hemorheologic properties. Transfusion 2015;55:1872-81.
37. Detterich J, Alexy T, Rabai M, et al. Low-shear red blood cell oxygen transport effectiveness is adversely affected by transfusion and further worsened by deoxygenation in sickle cell disease patients on chronic transfusion therapy. Transfusion 2013;53:297-305.
38. Nemeth N, Alexy T, Furka A, et al. Inter-species differences in hematocrit to blood viscosity ratio. Biorheology 2009;46:155-65.
39. Milnor WR. Cardiovascular physiology. New York: Oxford University Press; 1990.
40. Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 2014;371:1381-91.
41. Lacroix J, Hébert PC, Hutchison JS, et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med 2007;356:1609-19.
42. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368:11-21.
43. Schmalzer EA, Lee JO, Brown AK, et al. Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels. Implications for transfusion. Transfusion 1987;27:228-33.
44. Salazar Vázquez BY, Cabrales P, Tsai AG, et al. Lowering of blood pressure by increasing hematocrit with non nitric oxide scavenging red blood cells. Am J Respir Cell Mol Biol 2008;38:135-42.
45. Martini J, Carpentier B, Negrete AC, et al. Paradoxical hypotension following increased hematocrit and blood viscosity. Am J Physiol Heart Circ Physiol 2005;289:H2136-43.
46. Sriram K, Salazar Vázquez BY, Tsai AG, et al. Autoregulation and mechanotransduction control the arteriolar response to small changes in hematocrit. Am J Physiol Heart Circ Physiol 2012;303:H1096-106.
47. Yang X, Forouzan O, Burns JM, et al. Traffic of leukocytes in microfluidic channels with rectangular and rounded cross-sections. Lab Chip 2011;11:3231-40.
48. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368:22-33.
49. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84.
50. Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381-8.
51. Sadaka F, Trottier S, Tannehill D, et al. Transfusion of red blood cells is associated with improved central venous oxygen saturation but not mortality in septic shock patients. J Clin Med Res 2014;6:422-8.
52. Hébert PC, Wells G, Martin C, et al. Variation in red cell transfusion practice in the intensive care unit: a multicentre cohort study. Crit Care 1999;3:57-63.
53. Ghali JK, Anand IS, Abraham WT, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008;117:526-35.
54. Kulier A, Levin J, Moser R, et al. Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. Circulation 2007;116:471-9.
55. Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet 2011;378:1396-407.
56. Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 2011;365:2453-62.
57. Murphy GJ, Reeves BC, Rogers CA, et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation 2007;116:2544-52.
58. Murphy GJ, Pike K, Rogers CA, et al. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med 2015;372:997-1008.
59. Aapro M, Moebus V, Nitz U, et al. Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis. Ann Oncol 2015;26:688-95.
60. Ernst E, Matrai A, Kollar L. Placebo-controlled, double-blind study of haemodilution in peripheral arterial disease. Lancet 1987;1:1449-51.
61. Rudofsky G, Strubel G, Michler E, et al. Influence of fibrinogen and hematocrit on the early outcome of angioplasty in patients with PAOD. J Endovasc Ther 2004;11:125-31.
62. Bag S, Behera A, Khandelwal N, et al. Improvement in blood supply after “heparin-dextran” therapy in patients of Buerger's disease with critical limb ischemia. Indian J Surg 2013;75:462-8.